Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles

Go back to Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles

CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults

October 21, 2021 5:43 AM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor of updates to pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions (e.g., chronic conditions such as diabetes, chronic heart disease, chronic lung disease, or chronic liver disease, as well as HIV, an immunocompromising condition) or other disease risk factors (e.g., smoking, alcoholism). In both groups, the ACIP voted to... More

Merck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint

October 19, 2021 7:09 AM EDT

Merck (NYSE: MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trial Missing Primary Endpoint

Merck up 2.2%, Atea Still Halted... More